P-gp、MRP及CD44在膀胱癌组织中的表达及与预后的关系研究

程波; 张海芳; 牛凌卫

doi:10.13201/j.issn.1001-1420.2020.04.008

P-gp、MRP及CD44在膀胱癌组织中的表达及与预后的关系研究

- 安阳市人民医院泌尿外科(河南安阳, 455000)

详细信息

通讯作者: 程波,E-mail:chengbo1004@126.com

中图分类号: R737.14

收稿日期: 2019-04-15

Study on the expression of P-gp, MRP and CD44 in bladder cancer and their relationship with prognosis

- Department of Urology, Anyang People's Hospital, Anyang, Helan, 455000, China

More Information

Corresponding author: CHENG Bo, E-mail: chengbo1004@126.com

Received Date: 15 April 2019

摘要

摘要: 目的:探讨P糖蛋白(P-gp)、多药耐药蛋白(MRP)和(CD44)在膀胱癌中的表达及其与患者预后的关系。方法:选取2011年1月~2014年1月于我院住院经手术切除的膀胱尿路上皮细胞癌组织标本136例及癌旁正常组织60例,采用免疫组织化学方法分别检测P-gp、MRP和CD44的表达,并用统计学方法分析与临床病理学特征及预后相关因素的关系。结果:膀胱癌组织中P-gp、MRP和CD44的阳性表达率均高于癌旁正常组织,且差异有统计学意义(P<0.0001)。三者的表达跟患者年龄、性别及肿瘤大小均无关(P>0.05);而病理分级和临床分期低、淋巴结发生转移及复发的组织中P-gp和MRP表达越高,CD44在淋巴结转移、多发及复发组织中阳性率越高,差异有统计学意义(P<0.05)。Spearman结果显示,膀胱癌中CD44分别与P-gp、MRP的表达呈正相关(均P=0.000)。生存曲线分析显示3种蛋白表达阳性的患者5年生存率分别显著低于表达阴性的患者(P<0.05)。Cox比例风险模型分析结果显示P-gp、MRP和CD44的表达是影响膀胱癌预后的关键风险因素(P<0.05)。结论:P-gp、MRP和CD44在膀胱癌组织中均呈高表达,表达率随肿瘤的进展而增加,是影响患者预后的关键风险因素,阳性表达的患者5年生存率显著降低,今后可通过联合监测三者的表达水平以正确判断膀胱癌患者的预后效果。
- 膀胱癌 /
- P-gp /
- MRP /
- CD44 /
- 预后
Abstract: Objective: To investigate the expression of P-gp, MRP and CD44 in bladder cancer and its relationship with prognosis. Method: From January 2011 to January 2014, 136 cases of bladder urothelial cell carcinoma tissue samples and 60 cases of adjacent normal tissue samples that had been surgically resected in our hospital were selected. Immunohistochemical method was used to detect the expression of P-gp, MRP and CD44, and the relationship with clinicopathological features and prognostic factors was analyzed by statistical method. Result: The positive expression rates of P-gp, MRP and CD44 in bladder cancer tissues were higher than those in adjacent normal tissues, and the difference was statistically significant(P<0.0001). The expression of the three was not related to the patients' age, gender or tumor size(P>0.05). The higher expression of P-gp and MRP was found in the tissues with low pathological grade and clinical stage, lymph node metastasis and recurrence. The higher positive rate of CD44 was found in lymph node metastasis, multiple and recurrent tissues, and the difference was statistically significant(P<0.05). Spearman result showed that CD44 in bladder cancer was positively correlated with the expressions of P-gp and MRP, respectively(all P=0.000). Survival curve analysis showed that the 5-year survival rate of patients with positive expression of the three proteins was significantly lower than that of patients with negative expression(P<0.05). Cox proportional risk model analysis showed that the expressions of P-gp, MRP and CD44 were the key risk factors affecting the prognosis of bladder cancer(P<0.05).Conclusion: P-gp, MRP and CD44 are highly expressed in bladder cancer tissues, and the expression rate increases with tumor progression, which is a key risk factor affecting the prognosis of patients. The 5-year survival rate of patients with positive expression significantly reduced. In the future, the prognosis of bladder cancer patients can be correctly judged by the combined monitoring of the expression levels of the three.
- bladder cancer /
- P-gp /
- MRP /
- CD44 /
- prognosis

HTML全文

参考文献(26)

[1]	Grayson M.Bladder cancer[J].Nature,2017,551(7679):S33.
[2]	Antoni S,Ferlay J,Soerjomataram I,et al.Bladder cancer incidence and mortality:a global overview and recent trends[J].Eur Urol,2017,71(1):96.
[3]	Tommasi S,Besaratinia A.A versatile assay for detection of berrant DNA methylation in bladder cancer.[J].Methods Mol Biol,2018,1655:29-41.
[4]	赵宁,张新伟.膀胱癌的靶向药物治疗[J].国际肿瘤学杂志,2016,43(3):236-238.
[5]	田野.膀胱内药物灌注对浅表性膀胱癌术后复发的影响[J].中国基层医药,2017,24(2):235-238.
[6]	Van HS,Sparidans RW,Wagenaar E,et al.Breast cancer resistance protein(BCRP/ABCG2)and P-glycoprotein(P-gp/ABCB1)transport afatinib and restrict its oral availability and brain accumulation.[J].Pharmacological Research,2017,120:43-50.
[7]	Yuan Z,Shi X,Qiu Y,et al.Reversal of P-gp-mediated multidrug resistance in colon cancer by cinobufagin[J].Oncology Reports,2017,37(3):1815-1825.
[8]	Gameiro M,Silva R,Rocha-Pereira C,et al.Cellular models and in vitro assays for the screening of modulators of P-gp,MRP1 and BCRP[J].Molecules,2017,22(4):600.
[9]	Lin J,Ding D.The prognostic role of the cancer stem cell marker CD44 in ovarian cancer:a meta-analysis[J].Cancer Cell Int,2017,17(1):8.
[10]	Shen CJ,Kuo YL,Chen CC,et al.MMP1 expression is activated by Slug and enhances multi-drug resistance(MDR)in breast cancer.[J].Plos One,2017,12(3):e0174487.
[11]	Lee SH,Hu W,Matulay JT,et al.Tumor evolution and drug response in patient-derived organoid models of bladder cancer.[J].Cell,2018,173(2):515.
[12]	Mohd R,Nesam T,Kamaruzaman L,et al.Community acquired multi drug resistant(MDR)Acinetobacter baumanniipneumonia in malaysia-a case report[J].Respir Med Case Rep,2018,24:147-149.
[13]	Omran Z,Scaife P,Stewart S,et al.Physical and biological characteristics of multi drug resistance(MDR):An integral approach considering pH and drug resistance in cancer[J].Semin Cancer Biol,2017,43:42-48.
[14]	Lewis RH,Sharpe JP,Swanson JM,et al.Reinventing the Wheel:Impact of Prolonged Antibiotic Exposure on Multi-Drug Resistant Ventilator-Associated Pneumonia in Trauma Patients[J].J Trauma Acute Care Surg,2018,85(2):1.
[15]	Joshi P,Vishwakarma RA,Bharate SB.Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer[J].Eur J Med Chem,2017,138:273.
[16]	Tomono T,Yano K,Ogihara T.Snail-Induced epithelial-to-mesenchymal transition enhances P-gp-Mediated multidrug resistance in HCC827 cells[J].J Pharm Sci,2017,106(9):2642-2649.
[17]	杨福兰,余燕琪,习勋,等.不同分子亚型乳腺癌组织中BCRP、MRP1和MDR1的表达及其临床意义[J].南昌大学学报(医学版),2017,57(2):52-55.
[18]	Rady M,Mostageer M,Rohde J,et al.Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients.[J].Oncol Rep,2017,38(1):551-560.
[19]	Erdogan S,Turkekul K,Serttas R,et al.The natural flavonoid apigenin sensitizes human CD44 + prostate cancer stem cells to cisplatin therapy[J].Biomed Pharmacother,2017,88(2017):210-217.
[20]	Watanabe T,Okumura T,Hirano K,et al.Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer[J].Oncol Lett,2017,13(1):281-288.
[21]	Sun J,Sun B,Zhu D,et al.HMGA2 regulates CD44 expression to promote gastric cancer cell motility and sphere formation[J].Am J Cancer Res,2017,7(2):260-274.
[22]	Wang Z,Wang Q,Wang Q,et al.Prognostic significance of CD24 and CD44 in breast cancer:a meta-analysis.[J].Int J Biol Markers,2017,32(1):75-82.
[23]	Hu B,Ma Y,Yang Y,et al.CD44 promotes cell proliferation in non-small cell lung cancer[J].Oncol Lett,2018,15(4):5627.
[24]	Sachs J,Kadioglu O,Weber A,et al.Selective inhibition of Selective P-gp transporter by goniothalamin derivatives sensitizes resistant cancer cells to chemotherapy[J].J Nat Med,2019,73(1):226-235.
[25]	王文胜,马志强,张冠男,等.MRP1蛋白表达情况与乳腺癌新辅助化疗疗效的关系[J].癌症进展,2018,16(3):339-341.
[26]	Chen C,Zhao S,Karnad A,et al.The biology and role of CD44 in cancer progression:therapeutic implications[J].J Hematol Oncol,2018,11(1):64.